A study published in JAMA Oncology found that 1 in 6 cancer drugs approved between 2013 and 2018 were supported by randomized controlled trials (RCTs) that do not prove the drug’s superiority over the standard of care, as their control arms did not accurately represent the standard of care.  “The choice of control arm should be optimized to ensure that new cancer agents are truly superior to what most clinicians would prescribe outside a clinical trial setting. (docwire)